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Background: Immunohistochemistry (IHC) for napsin A has been widely used to support a diagnosis of lung
adenocarcinoma with high sensitivity. In this study, we evaluated immunoreactivity for napsin A in a broad
spectrum of renal neoplasms by using tissue microarrays (TMA).
Methods: Duplicate TMA of 159 surgically excised renal neoplasms of various types were constructed. IHC for
napsin A was performed on TMAs with appropriate positive and negative controls.
Results: Napsin A was expressed in Acquired cystic disease associated renal cell carcinoma (RCC) (2/2, 100.0%),
chromophobe RCC (5/45, 11.1%), clear cell RCC (10/23, 43.5%), clear cell papillary RCC (9/19, 47.4%), metanephric
adenoma (3/3, 100.0%), oncocytoma (13/23, 56.5%), and papillary RCC (31/37, 83.8%). Expression of napsin A was
not seen in mucinous tubular and spindle cell carcinoma (0/1, 0.0%), TFE/MITF RCC 0/1, 0.0%), and urothelial
carcinoma (0/6, 0.0%).
Conclusions: Napsin A is expressed in both common and rare sub-types of renal neoplasms with variable sensitivity.
Based on our results, napsin A is not specific for lung adenocarcinoma. When a metastatic carcinoma of unknown
primary is positive for napsin A, the differential diagnosis should include tumors of both renal and lung origin.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/9558727831304717.
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Napsin A is an aspartic proteinase [1], an enzyme of the
pepsin family. Napsin A is expressed in type II pneumo-
cytes and alveolar macrophages of the lung, the proximal
and convoluted tubules of the kidney, and acini and ducts
of the pancreas [1,2]. Immunohistochemistry (IHC) for
napsin A has been widely used to support a diagnosis
of lung adenocarcinoma with reported high sensitivity
(59% - 100%) [3-6], specificity (88 - 94%) [5,6], positive
predictive value (78 - 90%) [5,6], and negative predict-
ive value (72 - 96%) [5-7]. The reported sensitivity and
specificity of immunohistochemical labeling for napsin
A and TTF-1 for supporting the diagnosis of primary
lung adenocarcinoma are controversial due to differ-
ence in case number (155 vs. 1674 cases), and tumor
area (tissue block vs, tissue microarray) [6,7]. It is well
established that distinguishing primary lung adenocarcinoma* Correspondence: xlin@northwestern.edu
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unless otherwise stated.from squamous cell carcinoma, and neuroendocrine
carcinomas (including small cell carcinoma) is clinic-
ally important [3,4,7].
In addition to the expression of napsin A in lung
adenocarcinoma, immunoreactivity for napsin A has also
been documented in 5.3 - 48.3% of papillary thyroid car-
cinomas [3,4], 79.0 - 87.5% of papillary renal cell carcin-
omas (RCC) [3,4,7], 29.4 - 52% of clear cell RCC [3,4,7],
3.9 - 20.0% of chromophobe RCC [3,4], 5 - 20% of hepa-
tocellular carcinoma [6,7], and 8 - 20% of endometrial
adenocarcinoma [3,7]. Other tumor types, such as squa-
mous cell carcinoma (0 – 3% [7]), oncocytoma [3],
colonic adenocarcinoma (0 – 2% [7]), pancreatic adeno-
carcinoma (0 – 4% [7]), gastric adenocarcinoma, meso-
thelioma, ovarian carcinoma (0 – 6% [7]), urothelial
carcinoma, prostate adenocarcinoma, and breast adeno-
carcinoma (0 – 3% [7]), have been described as being
negative or very rarely positive for napsin A [3,4,6,7].
The new international society of urological pathology
(ISUP) Vancouver classification of renal neoplasia classi-
fies renal neoplasms into broad categories includingis is an Open Access article distributed under the terms of the Creative
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mors, mesenchymal tumors, mixed mesenchymal and epi-
thelial tumors, neuroendocrine tumors, hematopoietic
and lymphoid tumors, germ cell tumors, metastatic tu-
mors and other tumors [8]. As Napsin A has been shown
to be expressed in some types of epithelial neoplasms, in
this study, we evaluated the immunoreactivity for napsin
A in a broad spectrum of epithelial renal neoplasms classi-
fied according to the new ISUP classification—including
novel, recently described sub-types.
Methods
Patients
This study was approved by our Institution Review Board.
One hundred and fifty nine renal neoplasms that had
undergone resection at our institution between January 1,
2003 and December 31, 2012 were selected based on the
availability of H&E slides and sufficient tissue in the corre-
sponding paraffin blocks to perform the studies outlined
herein. All H&E slides from each case were reviewed
by a fellowship trained genitourinary pathologist (SMR).
The tumors were classified based on the international
society of urological pathology (ISUP) Vancouver clas-
sification of renal neoplasm [8]. These tumors included
45 chromophobe RCC, 37 papillary RCC, 23 clear cell RCC,
23 oncocytoma, 19 clear cell papillary RCC, 2 acquired
cystic disease associated RCC, 3 metanephric adenoma, 1
mucinous tubular and spindle cell carcinoma, 1 RCC
associated with an Xp11.2 translocations/TFE3 gene
fusion (TFE/MITF RCC), and 6 urothelial carcinomas
of the renal pelvis (Table 1).
Construction of tissue microarrays
After review of all H&E stained slides from a given case,
a single tumor containing paraffin block was chosen for
inclusion in a tissue microarray (TMA). For this study,
duplicate TMAs were constructed using 2 mm tissue
cores.Table 1 Expression of Napsin A in renal neoplasms
Neoplasms No. Napsin A No. (%)
Acquired cystic disease associated RCC 2 2 (100.0)
Chromophobe RCC 45 5 (11.1)
Clear cell RCC 23 10 (43.5)
Clear cell papillary RCC 19 9 (47.4)
Metanephric adenoma 3 3 (100.0)
Mucinous tubular and spindle cell carcinoma 1 0 (0.0)
Oncocytoma 23 13 (56.5)
Papillary RCC 37 31 (83.8)
TFE/MITF RCC* 1 0 (0.0)
Urothelial carcinoma 6 0 (0.0)
*: TFE/MITF RCC: RCC associated with Xp11.2 translocations/TFE3 gene fusions.Immunohistochemistry
An immunohistochemical (IHC) stain for Napsin A
(Catalog CM388CK, Biocare Medical, Concord, CA) was
performed on sections from the TMAs on an automated
stainer with appropriate positive (lung adenocarcinoma)
and negative controls (colon and prostate adenocarcin-
omas) [9]. Paraffin-embedded blocks were sectioned,
deparaffinized, rehydrated, and blocked with methanolic
3% hydrogen peroxide. Antigen retrieval was performed in
citrate buffer. After incubation with the primary anti-
Napsin A antibody, the detection was performed with
Iview DAB detection kit (Catalog number 760–091,
Ventana, Tucson, AZ). The cut off for positive staining
is at least 5% of cells with moderate or strong intensity
staining for napsin A. Only cytoplasmic dot staining
was recognized as positive stain. When evaluating the
TMA, the immunopositivity for macrophages and “edge
effect”, with positivity seen at the edges of the TMA
and negativity at the center of the TMA, should be
excluded [9].
Results
Expression of napsin a in renal neoplasms
Expression of napsin A was detected in most of renal
neoplasms with variable frequency (Table 1 and Figure 1).
High frequency of napsin A expression was found in ac-
quired cystic disease associated RCC (100.0%), metaneph-
ric adenoma (100.0%), oncocytoma (56.5%) and papillary
RCC (83.8%). For metanephric adenoma, the granular
cytoplasmic labeling was subtle relative to other tumor
types due to scant nature of the cytoplasm in metanephric
adenomas. Low frequency of napsin A expression was
found in chromophobe RCC (11.1%), clear cell RCC
(43.5%), and clear cell papillary RCC (47.4%). Expression
of napsin A was not detected in mucinous tubular and
spindle cell carcinoma, TFE/MITF RCC, or urothelial car-
cinoma of the renal pelvis.
Discussion
In this study, we found that napsin A is expressed in
various types of renal neoplasms with variable sensitivities.
Our results may have implications in various clinical
settings, including the evaluation of needle core biopsies
of renal masses and the work up of metastatic carcinomas
from unknown primary sites.
We found that immunoreactivity for napsin A was
seen in all acquired cystic disease associated RCC and
metanephric adenomas (100%). Approximately one-half
(47.4%) of the recently described entity clear cell papil-
lary RCC also labeled for Napsin A. Immunoreactivity
for napsin A was not seen in mucinous tubular and
spindle cell carcinoma or TFE/MITF RCC. To the best
of our knowledge, no study has previously reported on
the immunoreactivity of Napsin A in these specific renal
Figure 1 Expression of napsin A in various renal neoplasms. Photos of H&E stained slides (A, C, E, G, I, K, M, O, Q, and S) and IHC for napsin
A (B, D, F, H, J, L, N, P, R, and T) of Acquired cystic disease associated RCC (A and B), Chromophobe RCC (C and D), Clear cell RCC (E and F), Clear
cell papillary RCC (G and H), Metanephric adenoma (I and J), Mucinous tubular and spindle cell carcinoma (K and L), Oncocytoma (M and N), Papillary
RCC (O and P), TFE/MITF RCC (Q and R), and Urothelial carcinoma (S and T).
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distinguish these renal neoplasms, especially on renal bi-
opsy specimens.
In this study, we evaluated the immunoreactivity of
napsin A in a larger number of oncocytomas and chro-
mophobe RCC and found that immunoreactivity for
napsin A was seen in 56.5% oncocytoma, which is differ-
ent from a previous report (0%) [3]. This is probably due
to the inclusion of larger number of cases in our study
(23 vs. 3 cases), and the different antibodies used in the
studies (Biocare Medical vs. Novocastra) that may result
in difference in staining pattern due to different affinityto the antigen. Immunoreactivity for napsin A was de-
tected in 11.1% chromophobe RCC in our study, which
falls within the range of previously reported napsin A
immunoreactivity (2.9 – 20%) in this tumor type [3,4].
The huch higher rate of 20% immunoreactivity for nap-
sin A in chromophobe RCC previously reported may be
due to the limited number of cases used in the prior
study (5 cases vs. 45 cases in our study) [3]. The finding
of relative overexpression of napsin A in oncocytomas
versus chromophobe RCC (56.5% versus 11%) may be
helpful in distinguishing these two tumor types from
one another.
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A was present in several renal neoplasms with similar fre-
quencies as those reported previously. Immunoreactivity
for napsin A was detected in 43.5% clear cell RCC, which
is in the range of previously reported sensitivity (29.4 -
52%) [3,4,7]. We also found that immunoreactivity for
napsin A was seen in 83.8% papillary RCC, which is simi-
lar to prior published studies (79.0 - 87.5%) [3,4,7]. We
did not observe immunoreactivity for napsin A in urothe-
lial carcinomas of the renal pelvis, a finding which has
been noted by others [7].
Traditionally, all localized solid renal masses have been
considered potentially malignant and treated with surgi-
cal excision, most often radical nephrectomy, in an effort
to minimize the risk of metastatic dissemination [10].
However, renal biopsy has a definite and expanding role
in the evaluation and treatment of renal masses. Clinic-
ally, one of the most obvious uses of biopsy of kidney
masses is to distinguish a primary renal neoplasm from
a metastatic malignancy. Based on our results, if the bi-
opsied tumor is positive for napsin A, the differential
diagnosis is broad and should include both primary renal
tumors and metastatic tumors. Immunoreactivity for
napsin A can be seen in lung adenocarcinoma [3-7],
papillary thyroid carcinoma [3,4], hepatocellular carcin-
oma [6,7], and endometrial adenocarcinoma [3,7] as well
as the renal tumor subtypes identified in this study. In
general, if immunohistochemistry is required when
evaluating a needle core biopsy or cellblocks of a renal
mass a broad panel should be employed. A recent article
highlighted the utility of a panel that includes CA IX,
CD10, AMACR, CK7, and CD117 if the differential diag-
nosis is limited to common primary renal tumors—such
as clear cell RCC, papillary RCC, and chromophobe RCC
[11]. If the differential diagnosis of a tumor sampled by
needle core biopsy includes a metastatic carcinoma—such
as a lung metastasis, then additional markers such as
PAX8, TTF-1, and napsin A can be employed with the
caveat that none of these markers are 100% specific or
sensitive for a given diagnosis. When dealing with a napsin
A positive metastatic carcinoma of unknown primary in-
volving the lung, bone, liver, or other sites the immuno-
profile must be considered in the context of the clinical
and radiographic history. Essentially, the reader should be
wary of basing a diagnosis of site of origin solely on napsin
A labeling. Additionally it is important to be aware of the
fact that RCC frequently metastasizes to the lung and that
the majority of pulmonary metastases of RCC are of the
clear cell type. In our study, we found that 47.5% of clear
cell RCCs were positive for Napsina A. When dealing with
a tumor in the lung if the differential diagnosis includes
lung adenocarcinoma versus renal cell carcinoma includ-
ing clear cell RCC, IHC for TTF-1, PAX-8, and vimentin
in addition to napsin A may be helpful. Finally, based onprior reports nonpulmonary napsin A-positive tumors
generally stain weakly positive when compared to lung
adenocarcinoma. In addition, the presence of macro-
phages and background staining should be considered
when interpreting results [7]. One should also be aware of
the existence of TTF-1 negative, napsin A-positive pul-
monary adenocarcinoma.
We included a few uncommon renal tumors in the
study. Napsin A was immunoreactive in 2 of 2 (100%)
acquired cystic disease associated RCC, 3 of 3 (100%)
metanephric adenoma, 0 of 1 (0%) mucinous tubular
and spindle cell carcinoma, and 0/1 (0%) TFE/MITF
RCC. The definitive conclusion for Napsina A expres-
sion in these rare tumors with small case number needs
further studies by inter-institutional collaboration in
future.
Conclusions
In summary, our results show that napsin A is expressed
in a broad spectrum of renal neoplasms with varying
frequency. When a metastatic carcinoma of unknown
primary is positive for napsin A, the differential diag-
nosis should include tumors of both renal and lung origin.
if both renal cell carcinoma and lung adenocarcinoma are
in the differential diagnosis based on morphology and/or
clinical history a broad IHC panel including TTF-1, PAX-
8 and vimentin should be applied for a definitive
diagnosis. Napsin A may be a helpful marker in the
differential diagnosis of oncocytoma and chromophobe
RCC and further studies on this topic with a larger num-
ber of cases is warranted.
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